Blocking assembly of glycosylphosphatidylinositol (GPI) anchors to inhibit growth and increase immunogenicity of human fungal pathogens

Fungal pathogens cause life-threatening invasive infections in humans. Despite all available treatments, mortality rates remain unacceptably high, on par with deaths caused by infectious diseases such as tuberculosis and malaria. Alarmingly, the emergence of drug-resistant fungi is reducing already limited treatment options. To address needs for new antifungal medications, Amplyx Pharmaceuticals has developed fosmanogepix, a […]

Read More